This trial is testing a new drug to treat heart problems in people with hypertrophic cardiomyopathy.
- Hypertrophic Cardiomyopathy
2 Primary · 22 Secondary · Reporting Duration: Up to 124 Weeks
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
420 Total Participants · 2 Treatment Groups
Primary Treatment: Mavacamten · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
Frequently Asked Questions
Are new participants being added to this research project?
"Unfortunately, this particular clinical trial is not enrolling patients at the moment. The original posting was on October 31st, 2022 with the most recent update being on October 25th of the same year. Although there are no openings for this study, there are 236 other trials that have open recruitment periods." - Anonymous Online Contributor
In how many different medical clinics is this research study being conducted today?
"There are a total of 21 sites currently recruiting patients for this trial, which are based in cities including Grand Rapids, London and Kansas City. It would be most convenient to select the clinic nearest you to avoid any unnecessary travel." - Anonymous Online Contributor
When might Mavacamten be available to the public?
"Mavacamten's safety has been well-documented in Phase 3 trials, with efficacy seen in multiple rounds of testing. As such, it received a score of 3 from our team at Power." - Anonymous Online Contributor